

PRO PHARMACEUTICALS INC  
Form 8-K  
November 05, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of**  
**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 1, 2004**

---

**PRO-PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Nevada**  
(State or other jurisdiction  
of incorporation)

**000-32877**  
(Commission File Number)

**04-3562325**  
(IRS Employer  
Identification No.)

**189 Wells Avenue, Newton, Massachusetts**  
(Address of principal executive offices)

**02459**  
(Zip Code)

**Registrant's telephone number, including area code: (617) 559-0033**

**Not Applicable**

**(Former name or former address, if changed since last report.)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

(b)

Charles F. Harney, Chief Financial Officer of Pro-Pharmaceuticals, Inc., resigned effective November 1, 2004. Due to other commitments, Mr. Harney could not provide services to the Company on a full-time basis. We are appointing an executive search committee, which will include at least one person from our Board of Directors, to select a new full-time CFO. Mr. Harney has agreed to provide financial consulting services for a reasonable period while Pro-Pharmaceuticals conducts the executive search.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

By: /s/ David Platt

---

David Platt  
President and Chief Executive Officer

Date: November 5, 2004